Investor Relations



We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in eight FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.




  • Oct 29

    Regeneron Once Again Earns #1 Ranking in Science Magazine's Top Biopharma Companies to Work For
  • Oct 29

    FDA Accepts for Priority Review Libtayo® (cemiplimab-rwlc) for Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%


  • Jefferies Virtual London Healthcare Conference
    Nov 17
    7:20 AM EST
    Nov 17, 2020 | 7:20 AM EST

  • Cowen Virtual Presentation Series – 2020 IO Next Summit
    Nov 13
    1:15 PM EST
    Nov 13, 2020 | 1:15 PM EST

  • Credit Suisse 29th Annual Virtual Healthcare Conference
    Nov 9
    8:45 AM EST
    Nov 9, 2020 | 8:45 AM EST

  • Regeneron Pharmaceuticals Q3 2020 Earnings Conference Call
    Nov 5
    8:30 AM EST
    Nov 5, 2020 | 8:30 AM EST